menu
    • menu

    Company profile for Molecular Partners

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. We are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Molecular PartnersSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Wagistrasse 14\n8952 Zurich-Schlieren\nSwitzerland
    Telephone
    Telephone
    41 44 755 77 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.molecularpartners.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Molecular Partners Rethinks Dosing After Suboptimal Cancer Trial Results
    Molecular Partners Rethinks Dosing After Suboptimal Cancer Trial Results

    27 Aug 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/molecular-partners-rethinks-tetra-specific-dosing-after-seeing-suboptimal-exposure-cancer

    FIERCE BIOTECH
    27 Aug 2024
    Share Share
    Molecular Partners begins acute myeloid leukemia therapy trial
    Molecular Partners begins acute myeloid leukemia therapy trial

    17 Jan 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/molecular-myeloid-leukemia-therapy/

    CLINICAL TRIALS ARENA
    17 Jan 2023
    Share Share
    Molecular Partners Reports Corporate Highlights and H1 2022 financials
    Molecular Partners Reports Corporate Highlights and H1 2022 financials

    25 Aug 2022

    // PRESS RELEASE

    https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-corporate-highlights-and-h1-2022

    PRESS RELEASE
    25 Aug 2022
    Share Share
    Molecular Partners: Robbins LLP Reminds Investors of Lead Plaintiff Deadline
    Molecular Partners: Robbins LLP Reminds Investors of Lead Plaintiff Deadline

    22 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/22/2484698/0/en/Molecular-Partners-AG-Shareholder-Update-Robbins-LLP-Reminds-Investors-of-Lead-Plaintiff-Deadline-in-Class-Action-Against-Molecular-Partners-AG-MOLN.html

    GLOBENEWSWIRE
    22 Jul 2022
    Share Share
    Interim Management Statement Q1 2022 Of Molecular Partners
    Interim Management Statement Q1 2022 Of Molecular Partners

    12 May 2022

    // PRESS RELEASE

    https://investors.molecularpartners.com/news-releases/news-release-details/interim-management-statement-q1-2022-molecular-partners-cash

    PRESS RELEASE
    12 May 2022
    Share Share
    Molecular Partners To Participate In Upcoming Healthcare Investor Conferences
    Molecular Partners To Participate In Upcoming Healthcare Investor Conferences

    11 May 2022

    // PRESS RELEASE

    https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-participate-upcoming-healthcare-investor

    PRESS RELEASE
    11 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search